Magenta Therapeutics, Inc.
MGTA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.00 | 0.00 | 0.00 |
| FCF Yield | 0.00% | -875.80% | -1,011.76% | -697.08% |
| EV / EBITDA | 1.36 | 0.26 | 0.18 | 0.52 |
| Quality | ||||
| ROIC | -7.27% | -11.41% | -10.00% | -28.73% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.83 | 0.76 | 0.94 | 0.60 |
| Growth | ||||
| Revenue 3-Year CAGR | 1,998,816.08% | 1,965,218.75% | 1,948,419.59% | 1,840,440.96% |
| Free Cash Flow Growth | -27.66% | 13.44% | -45.14% | -126.23% |
| Safety | ||||
| Net Debt / EBITDA | 1.36 | 0.34 | 0.26 | 0.59 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 1,136.36 | 18.19 | 77.39 | 0.00 |